Short‐ and long‐term clinical and patient‐reported outcomes following laparoscopic ventral mesh rectopexy using biological mesh for pelvic organ prolapse: a prospective cohort study of 224 consecutive patients.

Abstract: Aim: Laparoscopic ventral mesh rectopexy (LVMR) is potentially a safe and effective operation to correct pelvic organ prolapse and to treat obstructive defaecation and solitary rectal ulcer syndrome. This study aimed to evaluate, in a prospective, consecutive cohort of patients, the long‐term clinical outcomes following LVMR, patient‐reported functional and quality of life outcomes, and urinary and sexual dysfunction. Method: Data on 224 patients who underwent LVMR with Permacol™ biological mesh were collected prospectively from May 2008 to October 2016. Outcome measures were complications, recurrence, mortality, patient satisfaction, patient‐reported functional and quality of life outcomes, and urinary and sexual dysfunction. Scores were compared using the two‐tailed Wilcoxon signed rank test. <italic>P </italic><<italic> </italic>0.05 was considered statistically significant. Results: There was no mortalities associated with LVMR in this series; complications occurred in 10.7% of patients (4.9% early, 5.8% late). Mesh‐related morbidity was 0.45% and vaginal suture‐related morbidity was 1.33%. Recurrence occurred in 25 patients (11.4%), 5% at 12 months, 10.7% at 5 years. Significant improvement in patient‐reported functional outcomes were seen (<italic>P </italic><<italic> </italic>0.001) for both constipation and faecal incontinence symptoms. Furthermore, significant improvement in quality of life outcomes for patients with constipation, faecal incontinence and prolapse persisted through follow‐up (<italic>P </italic><<italic> </italic>0.001). Patient satisfaction was positive for > 90% of patients during follow‐up. Symptoms of stress urinary incontinence, urge incontinence and dyspareunia improved significantly postoperatively (<italic>P </italic><<italic> </italic>0.001). Conclusion: LVMR using Permacol is associated with low morbidity and mortality, recurrence and, additionally, significantly improved constipation, faecal incontinence and prolapse functional and quality of life outcomes, with associated improvement in urogynaecological symptoms. [ABSTRACT FROM AUTHOR]